In an effort to help parents better understand why ignoring dental health can have serious consequences, and educate families about good dental health habits, the Ad Council and The Partnership for Healthy Mouths, Healthy Lives created new Public Service Ads (PSAs) for the Kids’ Healthy Mouths campaign. The new PSAs are humorous depictions of life lessons which make the point that while parenting can be tricky at times, getting kids to brush for two minutes, twice a day can be easier than most other things parents will try to teach their children. The new PSAs debut today at the American Dental Association (ADA) annual meeting and are now available for nationwide distribution.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7343051-kids-healthy-mouths-and-ad-council-launch-new-public-service-announcements/
Over 80% of Americans want to spend their last days at home, with friends and family. Yet, despite these desires, 75% of Americans will spend their last days in a hospital room. Many people will spend hours each day getting painful and often useless treatments and tests, and be asked to take dozens of debilitating drugs. For many, the cure is worse than the disease. This often has negative and lasting effects on family and friends who are often left with feelings of guilt and regret for years to come.
Hospice Support Fund is a 501(c)(3) non-profit organization dedicated to promoting end of life care at home rather than in a hospital so patients can spend their last days in dignity and peace, pain-free in familiar, comfortable surroundings with friends and family.
To view the multimedia release go to:
http://www.multivu.com/players/English/7785451-hospice-support-fund-end-of-life-care-psa/
Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).
To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy
Upsher-Smith Laboratories, Inc. today announced the nationwide launch of Provella™, a unique probiotic dietary supplement specifically designed for women to promote digestive, feminine, and immune health.* Provella™ helps restore and maintain balance of good bacteria to support digestive and vaginal health.* Taken once-daily by mouth, Provella™ tablets contain a proprietary blend of six bacteria strains that include: Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus fermentum, Lactobacillus reuteri, and Bifidobacterium bifidum.
Provella™ is available without a prescription behind the pharmacy counter at retail pharmacies nationwide and online at www.drugstore.com. Consumers can also ask any local pharmacist to order Provella™ using List Number 0245-1060-30.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56871-upsher-smith-provella-probiotic-supports-digestive-feminine-immune-health
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
St. Jude Children’s Research Hospital® officials and guests today marked the opening of the St. Jude Red Frog Events Proton Therapy Center, the first proton therapy center in the world dedicated solely to children with cancer.
Patients are now being treated at the center using precisely delivered, high-energy particles called protons to kill or shrink tumors while minimizing damage to healthy tissue and organs. For patients with brain tumors and certain other cancers, research suggests proton beam therapy may be more effective than conventional radiation at preventing the growth and spread of tumors while reducing the risk of treatment-related side effects.
To view the multimedia release go to:
http://www.multivu.com/players/English/7713451-st-jude-proton-therapy-opening/
Ever wondered what happens behind the doors of one of the world’s most established venues? IFSEC Global.com has got a backstage pass to the Royal Albert Hall to investigate how it keeps world-famous performers, and this iconic building, safe and secure.
Speaking to Amanda Squires, Director of Operations, an insight is given to the co-ordination of the 850 events delivered each year, as well as, the delicate procedure undertaken for getting modern CCTV and access control systems in place in this grade 1 listed building.
Amanda is joining the Protecting London panel debate at IFSEC International 2015, 16 – 18 June at ExCeL London, along with the British Museums’ Health & Safety Manager and Crossrail Ltd.’s Security Manager to discuss the considerations that need to be made when protecting such high value assets.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7537851-protecting-london-royal-albert-hall/
With September marking National Prostate Cancer Awareness Month and the kick-off of the 2015 NFL season, the Urology Care Foundation and the NFL have renewed their commitment to driving prostate health awareness, as well as teamed up to highlight a Public Service Announcement (PSA) focused on educating men about prostate cancer and encouraging them to take charge of their health through the Know Your Stats® campaign.
The Know Your Stats® campaign is a rallying force to connect, educate and inspire men across the country to know their prostate cancer risk and talk to their doctor about whether prostate cancer testing is right for them.
“It is important for men to know their risk and talk to their doctors so they can determine if prostate cancer testing is right for them,” said Richard A. Memo, MD, Chair of the Urology Care Foundation. “Having the tools and facts empowers individuals and their doctors to make informed decisions.”
Prostate cancer is the second most common cancer in America, affecting one in seven men. Odds increase to one in five if they are African American and one in three if they have a family history; however, the educational tools are making an impact. More men are talking with their doctors and getting tested, and fewer men are dying from the disease.
To view the multimedia release go to:
http://www.multivu.com/players/English/7365551-prostate-cancer-know-your-stats-psa/
Interim clinical results from Project IMPACT: Diabetes, announced today by the American Pharmacists Association (APhA) Foundation, show statistically significant decreases in A1C or blood sugar levels, LDL cholesterol, systolic blood pressure and Body Mass Index (BMI), which are all recognized standards of diabetes care. Participating patients in 25 communities who experienced improved outcomes encompass almost every socioeconomic class, insurance status and ethnicity.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62268-american-pharmacists-association-apha-foundation-project-impact-diabetes
Progresso is now using only 100 percent antibiotic and hormone free chicken breasts in all of its 36 chicken soup varieties. Currently available on store shelves nationwide, Progresso is the first large retail soup brand in the United States to have antibiotic and hormone free chicken breasts in its soups.
For decades, Progresso has been committed to continuously improving the quality of its soups. Not only is Progresso now using only white breast meat chicken with no antibiotics or hormones, but the brand is also free from artificial flavors and has removed artificial colors from 60 percent of its soups, with a goal to remove 100 percent by 2019. In addition, the soup brand has reduced sodium levels in more than 40 soup varieties, added seven soups to its certified Gluten Free product line and is increasing its vegetarian soup options.
To view the multimedia release go to:
http://www.multivu.com/players/English/7885251-progresso-antibiotic-free-chicken/
The following statement is being issued by Branstetter, Stranch & Jennings, PLLC regarding In re Prograf Antitrust Litigation.
A lawsuit is currently pending claiming that Astellas Pharma US, Inc. (“Astellas” or “Defendant”) violated state antitrust, unfair competition, consumer protection, and unjust enrichment laws of certain states by delaying the availability of a less expensive generic version of the immunosuppressant prescription drug Prograf® (known as tacrolimus). Plaintiffs allege that Defendant’s conduct caused some consumers and third party payors to pay too much for Prograf in certain states from September 3, 2008 to December 31, 2010 (also referred to as the “Class Damage Period”). This lawsuit does not claim that Prograf is unsafe or ineffective. Astellas denies any wrongdoing.
To view the multimedia release go to:
http://www.multivu.com/players/English/7933851-prograf-antitrust-class-action-settlement/
Available at: http://www.mitchellbrands.com/skin-lighteners
Professional Skin Lightening | Mitchell Group manufacturer of Professional Skin Lightening Products
These Skin Lightening products are formulated with only the highest quality ingredients that are totally safe and effective. They greatly enhance the health and look of the skin, restoring its natural glow and beautiful shine with a more even skin tone.
By Mitchell Group
http://www.youtube.com/watch?v=8b4my3KWMpo.
Researchers presenting at ASTRO 2015, the premier radiation oncology scientific event in the world, unveiled new data this week that could fundamentally change the way that early stage breast cancer is treated.
Results from a landmark prospective, randomized, multicenter phase III study conducted in Europe demonstrated that APBI brachytherapy leads to equivalent overall survival and local cancer control rates as compared to WBI after breast conserving surgery for selected patients with early stage breast cancers. These data were presented during the ASTRO official press conference and published in The Lancet, a leading high-impact global peer-reviewed medical journal.
“We have been confidently offering APBI brachytherapy to selected women for years based on numerous phase II, single site and large registry studies that have confirmed the clinical utility of site-specific radiation delivered in a condensed timeframe,” said Frank A. Vicini, M.D., radiation oncologist, 21st Century Oncology, Royal Oak, Mich. and contributing author to the 2009 and 2013 ASTRO and ABS APBI guidelines. “The results from this landmark, multicenter, prospective randomized clinical study are the first to offer the critical level one evidence necessary to drive the fundamental changes in breast conserving cancer treatment that patients and healthcare professionals have been demanding for years.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7661231-new-apbi-brachytherapy-data-at-astro-2015/
